Literature DB >> 6502251

An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan.

W H Beierwaltes, R Rabbani, C Dmuchowski, R V Lloyd, P Eyre, S Mallette.   

Abstract

Between January 1947 and June 1983, 511 patients were given treatment doses of I-131 after surgery for thyroid cancer in the presence of I-131 uptake in thyroid remnants. Thirty-four patients were removed from the study leaving 462 patients with a 99% follow-up at 1 or more yr, with a mean follow-up of 15 yr. Of 267 patients with radioiodine uptake confined to the thyroid bed, 233 (87%) had ablation from the first dose of I-131 ranging from 100 to greater than 200 mCi. The higher the percent uptake, the more difficult it was to achieve ablation. In the percentages of successful ablation, there were no significant differences between I-131 doses of: 100-149 mCi, 150-174 mCi, 179-199 mCi, and 200 mCi or more. The 100-149 mCi ablative dose may furnish "adjuvant" therapy for occult metastases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502251

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  25 in total

Review 1.  Radioiodine treatment of well-differentiated thyroid cancer.

Authors:  Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

Review 2.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

3.  S values for 131I based on the ICRP adult voxel phantoms.

Authors:  Stephanie Lamart; Steven L Simon; Andre Bouville; Brian E Moroz; Choonsik Lee
Journal:  Radiat Prot Dosimetry       Date:  2015-03-31       Impact factor: 0.972

4.  Expression of sodium iodide symporter in benign and malignant human thyroid tissues.

Authors:  J D Lin; C Hsueh; T C Chao; H F Weng
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

5.  INVESTIGATION OF THE INFLUENCE OF THYROID LOCATION ON IODINE-131 S VALUES.

Authors:  Yeon Soo Yeom; Daphnée Villoing; Natasha Greenstein; Cari M Kitahara; Les R Folio; Chan Hyeong Kim; Choonsik Lee
Journal:  Radiat Prot Dosimetry       Date:  2020-07-13       Impact factor: 0.972

6.  Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.

Authors:  Joseph J Grudzinski; Ronald R Burnette; Jamey P Weichert; Robert Jeraj
Journal:  Cancer Biother Radiopharm       Date:  2010-08       Impact factor: 3.099

Review 7.  Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.

Authors:  Nicholas S Andresen; John M Buatti; Hamed H Tewfik; Nitin A Pagedar; Carryn M Anderson; John M Watkins
Journal:  Eur Thyroid J       Date:  2017-03-23

8.  Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.

Authors:  Robbert B T Verkooijen; Marcel P M Stokkel; Jan W A Smit; Ernest K J Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

9.  Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.

Authors:  Seo Young Sohn; Joon Young Choi; Hye Won Jang; Hye Jeong Kim; Sang Man Jin; Se Won Kim; Sunghwan Suh; Kyu Yeon Hur; Jae Hyeon Kim; Jae Hoon Chung; Sun Wook Kim
Journal:  Thyroid       Date:  2013-06       Impact factor: 6.568

Review 10.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.